- Drugs
- Wednesday, 27 May 2020
Drugmaker Sanofi to raise over $11 billion by selling its U.S. partner Regeneron shares
Earlier this week, Regeneron had said it would repurchase about $5 billion of its shares directly from Sanofi, without altering their over-a-decade-long partnership.
Sanofi is selling the Regeneron shares at $515.00 per share - a discount of around 5.5% to Regeneron’s closing price of $545.21 on May 26, and raising gross proceeds of $11.1 billion.
Sanofi will continue to own approximately 400,000 shares of Regeneron’s common stock.
Sanofi could end up raising $11.7 billion, if the underwriters on the deal exercise their option to buy up a further 1.2 million Regeneron shares.
The collaboration between Sanofi and Regeneron dates back to 2003 and has resulted in five approved treatments to date - including eczema drug Dupixent - with additional candidates in clinical development.
Investment banks Bank of America Securities, Goldman Sachs, Barclays, BNP Paribas, Citigroup, JP Morgan and Morgan Stanley worked on Sanofi’s Regeneron stake sale.
Related Industry Updates
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Feb 13, 2020
ADHD Therapeutics Market is expected to reach US$ 64,742.37 million by 2030
Jan 29, 2024
CaaMTech Collaborates With National Institutes of Health to Research Psychedelics
May 08, 2020
Antibody Drug Conjugates Market is expected to reach US$ 29,600.98 million by 2030
Oct 04, 2023
Hikma receives FDA approval for its generic Vascepa®
May 22, 2020
What Is Human Serum Albumin and How It Drives Modern Medicine
Feb 25, 2026
Chronic Cough Market Key Factors and Emerging Opportunities with Current Trends Analysis 2027
Jul 13, 2020
Follow us on
